| Autor: |
Lai C; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Bhansali RS; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Kuo EJ; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA., Mannis G; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA., Lin RJ; Memorial Sloan Kettering Cancer Center, New York, NY. |
| Abstrakt: |
Over the past decade, our understanding of AML pathogenesis and pathophysiology has improved significantly with mutational profiling. This has led to translational advances in therapeutic options, as there have been 10 new US Food and Drug Administration (FDA) approvals for AML therapies since 2017, half of which target specific driver mutations in FLT3 , IDH1 , or IDH2 . These new agents have expanded the therapeutic armamentarium for AML, particularly for patients who are considered ineligible for intensive chemotherapy with anthracycline- and cytarabine-containing regimens. These new treatment options are relevant because the median age at diagnosis is 68 years, and outcomes for patients older than 60 years have historically been dismal. However, the optimal approach to incorporating novel agents into frontline regimens remains a clinical challenge, particularly with regard to sequencing of therapies, considering the role of allogeneic hematopoietic stem cell transplantation and managing toxicities. |
